Should patients with symptomatic coronary artery disease plus aortic valve disease of borderline clinical significance have aortic valve replacement at the time of initial CABG?  by Hochrein, James et al.
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screening of CP pts presenting to the ER could result in marked financ:al 
savings by eliminating unnecassaP/hospitalization. 
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Two Year Cardiac Cost After Cardiac catheterization 
- ~ Profound Impact of Revascularization After First 
PTC,~ Compared With Initial Medical or Surg;cal 
Therapy 
Stephen G. Ellis, Kimhody Brown, Gan Howell, Cheryl Ke~ck. 31eveland 
Clinic Foundalfon, Clevetan~ Ohio 
As capitation becomes the main form of payment for medical care, a shift 
in focus from in-hospltsl to long term cost of care will occur. Our database 
was queried to find all patients (pts) undergoing oath at the Cleveland Clinic 
(CCF) during 1993-4 who reported by that they received all lcllow-up cardiac 
care at CCR 38 data elements were compared to cost as determined by 
the Transition System Inc method. In a preliminary study, 350 pts (age = 
66 ± 10 yr, 38=/0 unstable angina, 25% prior CABG; initial treatment CABG 
= 28%, peroutanecus (pore) = 36%; follow-up 25:1:7 runs) were studied. 
24 month event-free (CABG, infarction) survival was 80% and cost $30822 
± 22709 {in 1993 $). P re -~ent  independent correlates of cost wore # 
medical comorbidities (e.g. azotomla) (+$2144/ea), oath status (emergency 
> urgent > elective), # diseased vessels (+$35011ea), smoking (+$5324). 
After adjustment for these factors, mean cost ($ x 1000) by initial (+follow 
up) treatment and # of diseased vessels is shove: 
l Vessel El Mad, o Pare x 1, V Perc x ~2, i Multivessel 5o l I^ oP~+CA~a.,, ^ I] + CA.G. / i~* -o  
o 
Heap 6 me. 12 mo.18 mo24 me. Hosp 6 me. 12 mo.18 mo.24 me. 
*p = 0,07 vs, medicine *p = 0.002 vs. ~BG 
Conclusions: For single vessel disease, initial pare may be cost effective 
vs. mad rx. For multi-vessel disease pts likely to need >_ 2 perc probably 
should have initial CABG. 
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~ Feladipine and Matoprolol CR In the Treatment ER 
of Patients With Stable Angina Pectods (FEMINA) 
An He Liem, Peter H. Dunselman, for the Working Group on Cardiovascular 
Research The Netherlands. Breda, The Netherlands 
The aim of the present study was to compare the substitution of metoproldi 
100/200 mg CR (M) by felodipine 10 mg ER (F) and the addition of F to 
M with continuation of M (control), in patients with stable effort angina and 
a positive exercise test despite optimal treatment with M. Accordingly, 356 
patients (mean age 62.6; resting heart rate < 65 bpm) were randomized to 
substitution of Mwith F (n = lf8), addition of Fto M (n = 119), or continuation of 
M (n = 119), Baseline characleristi~ did not differ significantly. Analysis was 
performed with the intention to treat approach, between group comparison 
of changes. Results after 5 weeks treatment am shown as changes from 
baseline. 
time until: F M + F M (control) 
End of exercise (e) 7 (35) 11 (43) 11 (43) 
Chest pain (e) 17 (66) 24 (62) (51) 
1 mm ST depression (s) 31 (72) 52 (59)* 13 (71) 
RPP at highest comparable 5511 (4030) *'~ -t031 (3068) -121 (3212) 
exert, level (mmHg/mfn) 
Adverse Events (no of patients) 50"* 28 19 
Mean (SD); *P < 0.05 vs M and F; ='P < 0.05 ve M + F and M 
Conclusion: addition of F to M results in beneficial effects on myoCardial 
ischemia during exercise, such as delaying time until onset of ST depression. 
Substitution of M with F results in comparable xercise results, at the expense 
of more adverse events and an Increase in rate pressure product (RPP) 
compared to M. In patients with symptomatic angina despite optimal /~- 
blockade, addition of F is to be preferred to substitution with F. 
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~ Efficacy end Safety of High 11boracic Epidural 
Analgesia Producing Sympathatl¢ Blockade to Treat 
Medically and Surgically Refractory Angina Pectoris 
Patdcla Gramllng-Babb, Michael J. Miller, ~¢ott 1". Reeves, A. 
Jackson Cmmbley, John R. Handy, Sunll J. Petal, Brian G. Cuddy, 
Raymond C. Roy, Michael R. Zile. Medical UnivereltyofSC, VA Medical 
Center, Charleston, SC 
Surgical ~ympethectomy Can relieve symptoms of angina in patients with 
refractory angina, However, in these high flsk patients this extensive surgery 
results in a high morbidity and mertafity. This same sympathetic I~ockade 
can now be produced using high.th0raclc epidurat analgesia (HTEA). Dudng 
the past 12 months, we treated 10 consecutive patients with NYHA Class IV 
angina despite three drug therapy (nitrates, beta-bleckede, calcium channel 
blockade) with HTEA. In 8 men and 2 women, age 58 =1:5 years, with 
extensive 3 vessel corena|y disease and ejection fraction 40 ± 5%, HTEA 
(T~-T4) was placed either pamutaneously or surgically with radiographic 
confirmation (by fluoroscopy or CT scan) of placement. Buplvaoaine (amide 
local anesthetic, 0.25-0.5%) was given as a bolus and then maintained either 
as a continuous infusion or an intermittent rebelus. A catheter was placed 
for 7 days in 4 patients, 14 clays in 3 patients and 90 days in 3 patients. 
Results: Prior to HTEA, each patient was deemed unsuitable for corenan] 
bypass surgery or percufaneous camnery angieplasty and had NYHA Clnss 
IV symptoms of angina, Six of 10 patients required intravenous nitroglycerin 
and h~n and were unable to be discharged from the intensive care unit. 
Two patients l~lulred an intra-ecrtic balloon pump. Following HTEA, all 10 
patients had improved symptoms with 5 patients improving to NYHA Class 
II symptoms and 5 to Class IlL All 5 patients on IV nttroglycedn, hep~n 
or int~a-aortic balloon pump had these mndalifies discontinued. Nine of 10 
patients were subsequently discharged from the hospital. One patient died 
of a noncardiao cause. Them wee no catheter elated deaths. There were 
2 catheter related complications necessitating catheter emoval. O~e patient 
developed a local infection and one had catheter occlusion secondary to 
fibrosis. No patient suffered a myocardial infarction or a significant arrbythmia. 
Condusion: In patients with otherwise intractable angina pectods, HTEA is a 
safe, effective mndality which produces ymptomatic relief of angina pactods 
and an increased activity level. 
Surgery  fo r  Va lves  and  Aneurysms 
Monday, March 25, 1996, 4:00 p .m. -5 :30 p.m. 
Orange County Convent ion Center, Room 315 
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Should Patients W'dh Symptomatic Coronary Artery 
Disease Plus Aortic Valve Disease of Borderline 
Clinical Significance Have Aortic Valve Replacement 
at the Time of Initial CABG? 
James Hochmin, John C. Lucks, J. Kevin Harrison, Thomas M. Bashom, 
Walter G. Weft, Robert H. Jones, James E. I.owe, William D. White, Donald 
D. Glower. Duke University, Durham, NC 
Few data exist to help the clinician decide whether to proceed with aortic 
valve replacement (AVR) at the time of CABG In patients with symptomatic 
coronary artery disease (CAD) and aottlc valve (AV) disease of borderline 
clinical significance. In order to understand the outcomes of AVR combined 
with CABG vs. CABG alone, we compared 62 patients (Group t) with aortto 
insufficiency (2 + orgreater) and/or aortic stenasis (mean aortic valve gradient 
of 10 mm Hg or greater) felt not to be significant enough to warrant AVR with 
414 patients (Group 2) who had the combined procedure. 
No significant differences in all-cause or cardiac mortality existed between 
the treatment groups. However, patients In Group 1 required renporetion 
for AVR significantly more often then Group 2 patients. The results were 
unchanged after controlling for EF, age, heart failure class, year of surgery 
and type of AV disease. 
6 Year Follow.up" Group I Group 2 
CABG Only AVR + CAEG 
All Cause Mortal~ 39.7% 39.1% p = 0.81 
Cardiac Mortality 34.3% 22,9% p :  0.35 
AV Reoperation 24.3% 3.0% p = 0.0003 
"Kaplan-Meier Estimates 
These results demonstrate that, In patients with symptomatic GAD and 
borderline clinically significant AV disease, replacing the AV at the time of 
initial CABG will significantly reduce the need for aortic valve reoporation 
without increasing mortality. 
